CARMAT's Financial Calendar for 2025
CARMAT, a pioneer in the MedTech industry, is thrilled to reveal its indicative financial calendar for 2025. The company is renowned for developing the Aeson artificial heart, offering hope for many suffering from advanced biventricular heart failure. This document outlines the significant financial events planned for the upcoming year, promising insights into CARMAT's evolving journey.
Important Financial Events
As we gear up for 2025, CARMAT is set to publish key financial results and host events that will provide stakeholders with a closer look at its performance and strategic directions.
Full-Year Results
One of the first major events will be the release of the full-year results for 2024, scheduled for April 29, 2025. This occasion is imperative for shareholders and investors keen to understand the company’s financial health and operational efficiency.
Shareholders’ Meeting
Another significant date is the shareholders' meeting, which will take place on June 26, 2025. This gathering will allow investors to engage directly with the company’s leadership, posing questions and discussing future prospects.
Half-Year Results
Subsequently, CARMAT will reveal its half-year results for 2025 on September 10, 2025. These timely updates will shed light on the company's progress in achieving its strategic goals throughout the year.
About CARMAT
Founded in 2008, CARMAT specializes in designing and producing the Aeson artificial heart, the world's first physiological artificial heart. The company’s mission is to present Aeson as a viable alternative to heart transplantation, addressing the acute shortage of donor organs available for patients in dire need.
Aeson is celebrated for its innovative technology, featuring a highly hemocompatible and pulsatile design that mimics the natural heartbeat. It is currently used as a bridge-to-transplant solution within the European Union and countries that recognize CE marking. In the U.S., it is undergoing evaluation through an Early Feasibility Study, aiming to expand its availability.
The company operates from its headquarters in Vélizy-Villacoublay, with production activities based in Bois-d'Arcy, harnessing the expertise of around 200 highly skilled professionals dedicated to advancing the technology and patient care.
Engagement and Information Access
CARMAT remains committed to transparency and engagement with its stakeholders. For those wanting further information, they can explore CARMAT's official website and stay connected through social media platforms. The dedication to innovative solutions, coupled with active communication strategies, reinforces CARMAT's mission.
Frequently Asked Questions
What is CARMAT's primary product?
CARMAT primarily designs and manufactures the Aeson artificial heart, aimed at patients suffering from advanced heart conditions.
When will CARMAT release its 2024 full-year results?
The full-year results for 2024 will be announced on April 29, 2025.
What is the significance of the shareholders' meeting?
The shareholders' meeting, scheduled for June 26, 2025, provides an opportunity for investors to engage with the company's management and discuss future developments.
How does Aeson work?
Aeson replicates the natural heart's function with a design that is self-regulated and hemostatically compatible, providing life-saving support to patients until a transplant can occur.
Is Aeson available in the United States?
Aeson is currently available in the U.S. only through an Early Feasibility Study approved by the FDA.
